We evaluated effects of teriparatide injection on hip structure among a subset 558 postmenopausal women enrolled in the Fracture Prevention Trial
Teriparatide increased bone mass and improved bone geometric strength in both treatment groups compared to the placebo group, with the response being dose-related
Local cortical instability characterized by the buckling ratio decreased by 5.5% and 8.6% in the teriparatide 20 μg and TPTD40 groups, respectively, during the study period
These data were presented in part at the American Society for Bone and Mineral Research meeting held in Minneapolis, Minnesota on September 19–23, 2003
Need more features? Save interactive summary cards to your Scholarcy Library.